<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="754">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04561193</url>
  </required_header>
  <id_info>
    <org_study_id>033.PHA.2020.A</org_study_id>
    <nct_id>NCT04561193</nct_id>
  </id_info>
  <brief_title>Investigation of Subsequent and Co-infections Associated With SARS-CoV-2 (COVID-19)</brief_title>
  <official_title>Investigation of Subsequent and Co-infections Associated With SARS-CoV-2 (COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Methodist Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Methodist Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter retrospective chart review of patients admitted to any of the four Methodist
      Health System hospitals
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter retrospective chart review of patients admitted to any of the four Methodist
      Health System hospitals (Methodist Richardson, Methodist Mansfield, Methodist Charlton, or
      Methodist Dallas) between February 1 and April 30, 2020. All study center utilize Epic Â®
      electronic health record (Verona, Wisconsin; www.epic.com) for which all data will be
      extracted from.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 30, 2020</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of subsequent and co-infections</measure>
    <time_frame>Feb 2020 - April 2020</time_frame>
    <description>Prevalence of subsequent and co-infections</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>Feb 2020 - April 2020</time_frame>
    <description>In-hospital mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay (LOS)</measure>
    <time_frame>Feb 2020 - April 2020</time_frame>
    <description>Hospital length of stay (LOS)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Retrospective Cohort</arm_group_label>
    <description>Patients admitted to Methodist Richardson, Methodist Mansfield, Methodist Charlton, or Methodist Dallas Medical Centers between February 1, 2020 and April 30, 2020 with positive COVID-19 PCR test.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational</intervention_name>
    <description>Observational</description>
    <arm_group_label>Retrospective Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with positive COVID-19 PCR test admitted to Methodist Richardson, Methodist
        Mansfield, Methodist Charlton, or Methodist Dallas Medical Centers between February 1, 2020
        and April 30, 2020.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients admitted to Methodist Richardson, Methodist Mansfield, Methodist Charlton, or
             Methodist Dallas Medical Centers between February 1, 2020 and April 30, 2020

          -  &gt;18 years old

          -  Positive SARS-CoV-2 (COVID-19) PCR test

        Exclusion Criteria:

          -  Outpatient or emergency department visit

          -  Not admitted to an inpatient or observation status for &gt;24 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Matthew Crotty, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Methodist Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Crystee Cooper, DHEd</last_name>
    <phone>214-947-1285</phone>
    <email>crysteecooper@mhd.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paola Gregoire, MS, MBA</last_name>
    <phone>214-947-4604</phone>
    <email>paolagregoire@mhd.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Methodist Dallas Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Crotty, PharmD</last_name>
      <phone>214-941-2400</phone>
      <email>matthewcrotty@mhd.com</email>
    </contact>
    <investigator>
      <last_name>Matthew Crotty, PharmD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ronda Akins, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ed Dominguez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 22, 2020</study_first_submitted>
  <study_first_submitted_qc>September 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2020</study_first_posted>
  <last_update_submitted>September 22, 2020</last_update_submitted>
  <last_update_submitted_qc>September 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coinfection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

